Previous Page
Funds
Name Truecaller
Target
Boost international expansion
Investors Open Ocean
Open Ocean invests in Truecaller to help boost international expansion INVESTOR
Open Ocean. Others undisclosed.
TARGET Truecaller will boost their international expansion in their key markets in North America, Asia and the Middle East.
PEOPLE Truecaller is a global crowdsourced phone directory available on iPhone, Android, Symbian (S60 & S40), Blackberry, Windows Phone and on the web.
Truecaller has millions of users that currently perform more than 120 million searches each month and the user base increases rapidly. Turecaller’s users, from all over the world, share their phone books, including numbers to pre-paid phones, and together create a relevant global directory – users can easily opt-in or out at any time. Founded in Stockholm, Sweden, 2009 Truecaller is owned by the founder duo, angels and VC company Open Ocean.
AyoxxA Biosystems Closes Series A Financing Round
FUND AyoxxA Biosystems, an international biotechnology company, announces it has closed a 2.6 million Euro Series A financing round.
INVESTOR The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten.
TARGET The funds raised will be used to drive the further development of AyoxxA’s proprietary platform technology and the scale-up of production of its novel bead-based biochips as the company moves towards commercialization.
PEOPLE AyoxxA, an international biotech company based in Cologne, Germany, and Singapore, has developed a proprietary technology platform for multiplexed protein analysis. Core to this cutting-edge technology are “In-situ Encoded Bead-based Arrays” (IEBA) which allow simultaneous, precise and cost effective protein analysis in very small sample volumes.
These novel biochips allow users to combine high throughput screening and multiplexed assay formats at the same time and thus have the potential to revolutionize applications in biomedical research, pharmacological screening, and diagnostics.
Name AyoxxA Biosystems
Target To drive the further development of AyoxxA’s proprietary platform technology and scale-up production of its novel bead- based biochips
Investors Wellington Partners Venture Capital, NRW.BANK, HTGF - High-Tech Gründerfonds
Private Investors Rainer Christine & Dr Gregor Siebenkotten
ContinuumRx, Inc. Closes $7 Million in Equity Financing
Name
ContinuumRx Target
Continued growth throughout the Southeastern U.S.
Investors
Mitsui & Co. Global Investment, Inc., Health Enterprise Partners, L.P. (HEP), Fidelis Capital Partners, Redmont Venture Partners and Stonehenge Capital Company
FUND ContinuumRx announces that it has closed on $7 Million in new financing.
INVESTOR The financing was led by Mitsui & Co. Global Investment, Inc.; Health Enterprise Partners, L.P. (HEP); and local investors, including Fidelis Capital Partners, Redmont Venture Partners, and Stonehenge Capital Company.
TARGET The new capital is to be used for continued growth throughout the southeastern U.S. "Securing this growth capital from quality investors is vital to our long-terms goals," said Chuck Jett, ContinuumRx's Chairman and CEO. "We signed our first joint
venture agreement with the University of Tennessee Medical Center in November of 2010. Today, with our joint venture partners, we serve patients and physicians at eight major healthcare systems operating 30 hospitals and medical centers in Tennessee, Mississippi, and Alabama."
PEOPLE ContinuumRx is based in Birmingham, Alabama and develops joint ventures with market-leading health systems to seek to improve patient outcomes through better coordination in the hospital-to-home transition. Through its unique integrated model with health systems and their affiliated providers, ContinuumRx is creating a better model of care for patients with chronic and complex conditions.